On April 12, 2023, Denovicon Therapeutics Founder & CEO, Scott Bembenek, will present on ‘Enhanced Active Learning by Combining Machine Learning and Structure-Based Methods’ at the Drug Discovery Chemistry Conference: Artificial Intelligence for Early Drug Discovery – Part 2 in San Diego, CA.
Categories
Recent Posts
- Denovicon Introduces AI–Physics-Driven Multi-Objective Optimization Platform for Small-Molecule Drug Discovery
- Denovicon Therapeutics joins ARPA-H Investor Catalyst Hub Spoke Network
- Re-Inventing Drug Discovery
- Denovicon is Accepted into the 3DEXPERIENCE Lab Accelerator
- DRUG DISCOVERY CHEMISTRY CONFERENCE 2023